Pemetrexed

BreastfeedingPediatric
  • TRADE NAME: Alimta (Lilly)
  • INDICATIONS: Non-squamous non-small cell lung cancer, mesothelioma (in combination with cisplatin)
  • CLASS: Antimetabolite, Folic acid antagonist
  • HALF-LIFE: 3.5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Clozapine, Digoxin, Leflunomide, Meloxicam, Natalizumab, Nephrotoxic drugs, NSAIDs, Phenytoin, Pimecrolimus, Probenecid, Pyrimethamine, Sipuleucel-T, Tacrolimus, Trastuzumab, Vaccines

PREGNANCY CATEGORY: D

Our database has 116 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of pemetrexed in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 11/08/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top